Spectral AI, Inc. (MDAI) - Q1 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2026. Spectral AI, Inc. is an emerging growth company and smaller reporting company focused on predictive medical diagnostics using its DeepView® System. The company utilizes proprietary AI algorithms and multispectral imaging to assess burn wound healing potential. As of the reporting date, the company has not generated product revenue; all revenue is derived from research and development contracts with U.S. government agencies, primarily the Biomedical Advanced Research and Development Authority (BARDA).
Key Financial Metrics
| Metric (in thousands) | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $3,991 | $6,707 |
| Gross Profit | $2,027 | $3,168 |
| Gross Margin | 50.8% | 47.2% |
| Operating Loss | $(1,971) | $(896) |
| Net Loss | $(3,412) | $2,897 (Income) |
| Cash and Equivalents | $11,655 | $14,061 |
| Total Debt (Notes Payable) | $8,414 | $8,392 |
| Warrant Liabilities | $12,535 | $11,533 |
| Net Cash Used in Operating Activities | $(3,728) | $(1,505) |
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 40.5% to $3.99 million, driven by a 48.1% drop in BARDA contract revenue ($3.31M vs $6.38M) as the base phase of the contract concluded. This was partially offset by a 109.2% increase in revenue from other U.S. governmental authorities.
- Net Loss vs. Income: The company reported a net loss of $3.41 million compared to net income of $2.90 million in Q1 2025. The swing was primarily due to a $5.26 million change in the fair value of warrant liabilities (an expense of $1.0M in 2026 vs. a gain of $4.25M in 2025) and reduced operating revenue.
- Cash Burn: Cash decreased by $3.74 million during the quarter. Net cash used in operating activities increased to $3.73 million due to the higher net operating loss and a decrease in accounts payable.
- Debt and Warrants: Warrant liabilities increased to $12.5 million. The company holds approximately $8.4 million in outstanding debt, including the Avenue Financing facility.
Outlook, Management Commentary, and Risks
- BARDA Funding Acceleration: In March 2026, BARDA exercised options to accelerate $31.7 million in funding for follow-on development and procurement. The company committed to fund $9.7 million of the associated development costs. The contract includes an additional $63.4 million in options.
- Regulatory Status: The DeepView System received UKCA marking for burn indications in February 2024. A De Novo application for FDA Class II designation was filed in June 2025. Commercialization in the UK is anticipated to begin in 2026.
- Liquidity: Management believes current cash, combined with the BARDA contract, MTEC agreement, and Avenue Financing, is sufficient to fund operations for at least one year beyond the filing date.
- Internal Control Material Weakness: The company disclosed a material weakness in internal control over financial reporting related to the financial statement close process, account reconciliations, and transaction processing. Remediation efforts are underway, including hiring additional accounting personnel and enhancing ERP functionality.
- Executive Changes: Vincent Capone was appointed CEO in February 2026, and David McGuire was appointed CFO in April 2026.
Investor Verification Checklist
- Revenue Concentration: Verify the sustainability of revenue given that 83% of Q1 2026 revenue came from a single customer (BARDA).
- Warrant Liability Volatility: Assess the impact of the $12.5 million warrant liability on net income, as fair value adjustments caused a $5.3 million swing in other income/expense compared to the prior year.
- FDA Approval Timeline: Monitor the status of the FDA De Novo application filed in June 2025, as commercial revenue is contingent on regulatory clearance.
- Internal Control Remediation: Review future filings for confirmation that the material weakness in financial reporting controls has been remediated.
- Cash Runway: Confirm the company's ability to meet the $9.7 million co-funding commitment to BARDA without requiring immediate additional equity financing.